Digest Network Come funziona
Network
/
Società
La
Non verificato

Latus Bio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

5 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Infanzia
Vetrine/Shopping
Latus Bio Announces IND Clearance of LTS-101 for CLN2 Disease and Receipt of Fast Track, Orphan Drug, and Rare Pediatric Disease Designations
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Salute
Tecnica
Mercato del lavoro
Industria
Latus Bio Launches AI/ML Strategy to Transform AAV Gene Therapy, Adds Two Leading Experts in Peptide and Protein Modeling to Scientific Advisory Board
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
20/05/2025
Industria
Scienza
Biotecnologia
Sanità
Salute
Farmaceutica
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
14/05/2025
Industria
Salute
Biotecnologia
Scienza
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0
24/02/2025
Eventi
Fiere
Industria
Salute
Biotecnologia
Sanità
Farmaceutica
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program
Fonte
Latus Bio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0